JIM KOZUBEK, /www.statnews.comJun 26, 20171 minWho will pay for CRISPR?Despite its game changing technology, who will pay for CRISPR'S high cost? Will it be affordable; questions remain whether most insuranc
Mathew Shanley, www.raredr.comJun 25, 20171 minNew Data Provide Beneficial Evidence of Soliris (eculizumab) in PNH PatientsAlexion Pharmaceuticals, Inc. presented new data displaying benefits of Soliris (eculizumab) treatment for patients with PNH, regardless of
Mathew Shanley, www.raredr.comJun 25, 20171 minSeattle Genetics announced promising results from its Phase 3 ECHELON-1 in Frontline Advanced HodgkiTakeda and Seattle Genetics announced promising results from its Phase 3 ECHELON-1 Clinical Trial that evaluated Adcetris in Frontline Advan
